• |
  • |
  • |
  • |
Donate

Product

Journal: Molecular, Neurocognitive and Psychosis Risk Profiles in Youth and Young Adults With 22q11.2 Deletion Syndrome: Longitudinal Findings from a Multimodal Study

Center:
Fiscal Year:
2026
Contact Information:
Product Description:
Genetic classification of neurodevelopmental disorders (NDDs) may help anticipate treatment tolerability; additional prescribing considerations may be needed for those with rare variants. Current psychotropic prescribing practices do not differ across rare genetic NDD subgroups.
Keyword(s):
Product/Publication Type(s):
Peer-reviewed publications in scholarly journals Published/In Press
Target Audience:
Professionals
Alternative Format:
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A